2024-09-02 15:02:13
September 2, 2024
Purpose: to combat the spread of the virus. As the continental pox outbreak intensifies in Africa, the High Authority for Health has issued vaccination recommendations.
On August 14, 2024, the World Health Organization declared MPOX a public health emergency of international concern for the second time in two years. Monkeypox is currently spreading in the Democratic Republic of Congo and neighboring countries. A new strain (clade 1b) that is different from the one at the origin of the last epidemic is at work and is suspected to be more dangerous and contagious.
Mpox still exists in France
In France, France is one of 13 countries in the European zone where the Type IIb branch continues to spread quietly since the outbreak began in 2022, with 126 cases recorded since the beginning of the year. “It is against this background that, although immunity to orthopoxviruses has all but disappeared in the world’s population since the cessation of smallpox vaccination in the early 1980s, the Ministry of Health has urgently seized on HAS to reassess its approach to monkeypox. Vaccine Strategy Virus (MPXV)”, The High Authority for Health specified this in a press release on September 2.
HAS issued an opinion on vaccination, setting out three objectives:
Preventing the emergence of clade Ib in France; eliminating clade II cycles; and boosting immunity before possible outbreaks.
Health authorities recommend vaccination for high-risk groups:
Men who have sex with men and transgender people with multiple sexual partners; people who engage in prostitution; professionals in sex venues; partners and people who share the same living space with the above people.
The goals of vaccination remain the same as during the last outbreak, with close and sexual contact transmission still accounting for the majority regardless of branch.
Booster doses for people vaccinated in 2022
HAS also advocates reactive vaccination for identified cases (i.e. people who have been in contact with high-risk contacts and immunocompromised people who have been in close contact with high-risk contacts). This dose must be administered within 4 days (and at the latest 14 days) of hazardous exposure.
HAS details vaccination process : “Initial vaccination with MVA-BN vaccine (Imvanex or Jynneos) is two doses given at least 28 days apart, or a single dose for those who received the first-generation vaccine before 1980. For immunocompromised people, Regardless of a history of smallpox vaccination, two doses should be given, with a third dose given at least 28 days after the second dose.
It also recommends booster doses for people vaccinated in 2022.
1725309374
#Mpox #vaccination #recommendations #news
